Compare GERN & AVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | AVO |
|---|---|---|
| Founded | 1990 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1996 | 2020 |
| Metric | GERN | AVO |
|---|---|---|
| Price | $1.10 | $11.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $4.25 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 5.9M | 922.9K |
| Earning Date | 11-04-2026 | 09-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | 1.92 |
| EPS | ★ N/A | N/A |
| Revenue | $1,065,000.00 | ★ $1,391,200,000.00 |
| Revenue This Year | $28.49 | $4.60 |
| Revenue Next Year | $44.73 | $16.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.68 |
| 52 Week Low | $1.04 | $10.07 |
| 52 Week High | $2.01 | $15.53 |
| Indicator | GERN | AVO |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 39.15 |
| Support Level | $1.08 | $10.22 |
| Resistance Level | $1.26 | $13.35 |
| Average True Range (ATR) | 0.05 | 0.49 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 8.33 | 38.41 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.